✨ Free AI Report
Entera Bio Ltd.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Entera Bio Ltd.
Company Research

Entera Bio Ltd.: Business Overview, Financials & Competitive Analysis

Entera Bio is a clinical-stage company focused on developing oral peptide and protein replacement therapies for unmet medical needs, leveraging its proprietary N-Tab platform that stabilizes peptides and promotes abso...

Analyst-debate audio for Entera Bio Ltd.

AskCyborg analysts argue the bull and bear cases for Entera Bio Ltd. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Platform validation with dual-pathway programs (PTH, GLP-1/2) targeting massive markets, but execution depends on Phase 3 success...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Specialty Therapeutics (Oral Peptide Delivery)
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Entera Bio Ltd. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Entera Bio Ltd. Overview

Pro stress-test →

Entera Bio is a clinical-stage company focused on developing oral peptide and protein replacement therapies for unmet medical needs, leveraging its proprietary N-Tab platform that stabilizes peptides and promotes absorption into the bloodstream. The company is addressing large markets including osteoporosis, hypoparathyroidism, obesity, and rare malabsorption conditions where oral delivery could transform treatment paradigms currently dominated by injectable therapies.

Strategic Profile

Pro stress-test →

Entera achieved FDA alignment for EB613 in July 2025 and is pursuing strategic partnership discussions to optimize development and commercialization across its pipeline. The company appointed former Pfizer executive Geno J. Germano as Chairman in February 2026, signaling institutional strengthening ahead of key clinical milestones.

Competitive Landscape

Pro stress-test →

Entera competes in multiple therapeutic areas including oral GLP-1/glucagon peptides for obesity and GLP-2 for short bowel syndrome, currently dominated by injectable alternatives like semaglutide and Gattex. The company's primary competitive advantage is its N-Tab platform enabling oral delivery of large molecules where existing therapies require daily injections.

Industry Context

Entera Bio Ltd. operates in Biopharmaceutical - Specialty Therapeutics (Oral Peptide Delivery).

Key facts

Founded: 2009 · Headquarters: Jerusalem, Israel

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Entera Bio Ltd..

  • FDA qualified BMD as a regulatory endpoint for EB613 in December 2025, clearing pathway for Phase 3 osteoporosis trial planned for Q1 2026
  • Next-Gen EB613 Phase 1 bridging study initiated November 2025 with results expected end Q1 2026; company accelerating long-acting oral PTH (EB612) into clinic in 2026
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026Appointed former Pfizer executive Geno J. Germano as Chairman
  • Jan 2026Announced Q1 2026 corporate priorities including EB613 Phase 3 protocol submission and EB612 acceleration
  • +1 moreTrack every material event for Entera Bio Ltd. as it happens. Explore monitoring →
Get alerted when Entera Bio Ltd. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Semaglutide (Ozempic, Wegovy)Injected GLP-1 for obesity and diabetes→GattexInjected GLP-2 for short bowel syndrome→Teriparatide (Forteo)Injected PTH(1-34) for osteoporosis→CarbagluOral therapy for hyperammonemia in hypoparathyroidism→

Compare Entera Bio Ltd. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Entera Bio Ltd. operates in Biopharmaceutical - Specialty Therapeutics (Oral Peptide Delivery). See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Specialty Therapeutics (Oral Peptide Delivery) research →
NEW · MCP server

Ask your AI assistant about Entera Bio Ltd.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Entera Bio Ltd. and its top competitor on Cyborg Score”
“What did Entera Bio Ltd. do this quarter?”
“Is Entera Bio Ltd. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Entera Bio Ltd. do?+
Entera Bio is a clinical-stage company focused on developing oral peptide and protein replacement therapies for unmet medical needs, leveraging its proprietary N-Tab platform that stabilizes peptides and promotes abso...
What is Entera Bio Ltd.'s Cyborg Score?+
Entera Bio Ltd. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Entera Bio Ltd.'s main competitors?+
Named competitors include Semaglutide (Ozempic, Wegovy), Gattex, Teriparatide (Forteo), Carbaglu. The full competitive landscape is in the AskCyborg report.
How can I get the full Entera Bio Ltd. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Entera Bio Ltd. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Entera Bio Ltd. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical - Specialty Therapeutics (Oral Peptide Delivery) research

Companies in the same sector and named competitors, ranked by Cyborg Score.

6Entera Bio Ltd.